+++
title = "Dextromethorfan (DXM)"
description = "Disociativni antitusikum - NMDA antagonista a sigma-1 agonista s unikátním plateauvym davkovanim"
weight = 1

[taxonomies]
tridy = ["Morfinary"]
receptory = ["NMDA", "Sigma-1", "Opioidni", "SERT"]
zdroje = ["Synteticke", "OTC"]
+++

# Dextromethorfan - Disociativni antitusikum

**Dextromethorfan** (DXM) je synteticky derivat morfinu pouzivany primarne jako **antitusikum** (proti kasli). Pri vyssich davkach vykazuje vyrazne **disociativni** a psychedelicke ucinky prostrednictvim antagonismu [NMDA receptoru](@/receptors/nmda.md) a agonismu [sigma-1 receptoru](@/receptors/sigma-1.md). Je znamy svym unikatnim systemem "plateau" - ctyrech kvalitativne odlisnych urovni intoxikace.

---

## Chemicka struktura

### Zakladni parametry

| Vlastnost | Hodnota |
|-----------|---------|
| **Chemicky nazev** | (+)-3-methoxy-17-methylmorfinan |
| **Alternativni nazvy** | DXM, Robitussin, Dex, Tussin |
| **Molekularni vzorec** | C18H25NO |
| **Molekularni hmotnost** | 271,40 g/mol |
| **CAS cislo** | 125-71-3 |
| **IUPAC** | (9S,13S,14S)-3-methoxy-17-methyl-9alpha,13alpha,14alpha-morphinan |
| **SMILES** | COC1=CC2=C(C=C1)[C@]34CCN(C)[C@H]3CCC[C@@]24 |
| **PubChem CID** | 5360696 |
| **DrugBank ID** | DB00514 |
| **Pravotocivy enantiomer** | Ano (D-isomer) |

### Strukturni klasifikace

| Kategorie | Zarazeni |
|-----------|----------|
| **Trida** | Morfinany |
| **Podtrida** | 3-methoxymorfinary |
| **Chiralita** | Dextrorotatorni ((+)-isomer) |
| **Strukturni vztah** | D-isomer levorfanolu |
| **Puvod** | Synteticky |

### Porovnani s levorfanolem

```
DEXTROMETHORFAN (DXM)           LEVORFANOL
(+)-isomer                      (-)-isomer
        |                            |
   Disociativni                 Opioidni
   antitusikum                  analgetikum
        |                            |
   Slaba opioidni               Silna opioidni
   aktivita                     aktivita
        |                            |
   NMDA antagonista             Minimalni NMDA
   Sigma-1 agonista             aktivita
```

---

## Fyzikalne-chemicke vlastnosti

| Vlastnost | Hodnota |
|-----------|---------|
| **Teplota tani** | 109-112 C (volna baze) |
| **Barva** | Bila krystalicka latka |
| **Rozpustnost ve vode** | 1,5 mg/mL (volna baze) |
| **Rozpustnost HBr soli** | Dobre rozpustna |
| **pKa** | 8,3 |
| **logP** | 3,6 (lipofilni) |
| **Biologicky polocas** | 2-4 hodiny (DXM), 3-6 h (DXO) |
| **Vazba na proteiny** | ~60% |

### Farmaceuticke formy

| Forma | Koncentrace | Poznamka |
|-------|-------------|----------|
| **Sirup** | 10-15 mg/5 mL | Nejbeznejsi |
| **Tablety** | 15-30 mg | Extended-release |
| **Gelove kapsle** | 15-30 mg | Rychle uvolnovani |
| **Prasek** | Cista latka | Nezakonne pouziti |

---

## Historie

### Vyvoj a schvaleni

| Rok | Udalost | Vyznam |
|-----|---------|--------|
| **1954** | Synteza (Hoffmann-La Roche) | Hledani nenavykoveho antitusika |
| **1958** | FDA schvaleni | Nahrada kodeinu |
| **1960s** | Prvni zpravy o zneuzivani | Romilar (stazeny 1973) |
| **1970s** | OTC dostupnost | Robitussin, NyQuil |
| **1990s** | Internetova kultura | "Robotripping" fenomen |
| **2010** | DXM + Quinidin (Nuedexta) | FDA pro PBA |
| **2022** | DXM + Bupropion (Auvelity) | FDA pro MDD |

### "Robotripping" subkultura

Termin odvozeny od znacky Robitussin:
- **1990s**: Rozsireni na internetu (Usenet, early web)
- **DXM FAQ**: William White's comprehensive guide (1995+)
- **Plateau system**: Systematizace urovni intoxikace
- **2000s**: Zvyseny monitoring, age restrictions

---

## Farmakologie

### Receptorovy profil

| Receptor | Ki (nM) | Ucinek | Funkce |
|----------|---------|--------|--------|
| **[NMDA](@/receptors/nmda.md)** | ~2,000-8,000 | Antagonista | Disociace, antideprese |
| **[Sigma-1](@/receptors/sigma-1.md)** | 100-200 | Agonista | Neuroprotekce, modulace |
| **SERT** | 23-40 | Inhibitor | Serotoninergni efekt |
| **NET** | >10,000 | Slaba inhibice | Minimalni |
| **nACh (alpha-3-beta-4)** | ~700 | Antagonista | Antitusivni |
| **Opioidni (mu)** | >10,000 | Zanedbatelna | Minimalni analgezie |
| **Opioidni (delta)** | >10,000 | Zanedbatelna | Minimalni |

### DXM vs Dextrorfan (DXO)

| Parametr | DXM | DXO (metabolit) |
|----------|-----|-----------------|
| **NMDA Ki** | 2,000-8,000 nM | 500-900 nM |
| **Sigma-1 Ki** | 100-200 nM | 50-120 nM |
| **SERT Ki** | 23-40 nM | 400+ nM |
| **PCP-like efekt** | Slabsi | Silnejsi |
| **Serotoninergni** | Silnejsi | Slabsi |

### Mechanismus antitusivniho ucinku

```
KASEL REFLEX
     |
     v
Aferentni vlakna (vagus)
     |
     +---> Nucleus tractus solitarius
              |
              v
         Kaslove centrum (medulla)
              |
              +---> [DXM blokada]
              |     - Sigma-1 modulace
              |     - nACh antagonismus
              |
              v
         Efektor (kasel potlacen)
```

### Mechanismus disociativnich ucinku

```
DXM peroralne
     |
     v
Metabolismus (CYP2D6)
     |
     +---> DXM (sigma-1 agonista, SERT inhibitor)
     |
     +---> DXO (potentni NMDA antagonista)
              |
              v
[NMDA receptor blokada] (extrasynapticka)
              |
              v
Snizena glutamatergni transmise
              |
              v
Kortiko-talamicka disociace
              |
              v
DISOCIATIVNI STAVY
- Depersonalizace
- Derealizace
- Zmenena percepce casu
- Halucinace (vyssi davky)
```

---

## Farmakokinetika

### Absorpce a distribuce

| Parametr | Hodnota |
|----------|---------|
| **Biodostupnost** | ~11% (extensive metabolizers) |
| **Tmax** | 1,5-2,5 hodiny |
| **Vd** | 5-6 L/kg |
| **Prostup HEB** | Ano (lipofilni) |

### Metabolismus - CYP2D6 polymorfismus

```
DXM
 |
 | [CYP2D6] - KRITICKY ENZYM
 | (O-demethylace)
 v
Dextrorfan (DXO) - aktivni
 |
 | [CYP3A4]
 | (N-demethylace)
 v
3-Hydroxymorfman
 |
 v
Glucuronidace -> Eliminace

ALTERNATIVNI CESTA (poor metabolizers):
DXM
 |
 | [CYP3A4]
 | (N-demethylace)
 v
3-Methoxymorfman
 |
 v
Glucuronidace -> Eliminace
```

### CYP2D6 fenotypy a efekt

| Fenotyp | Populace | DXM:DXO pomer | Zkusenost |
|---------|----------|---------------|-----------|
| **Extensive (EM)** | 70-80% | Normalní | Typicka |
| **Intermediate (IM)** | 10-15% | Zvyseny DXM | Intenzivnejsi |
| **Poor (PM)** | 5-10% | Velmi vysoky DXM | Velmi intenzivni, rizikove |
| **Ultrarapid (UM)** | 1-5% | Nizky DXM | Slabsi ucinek |

**VAROVANI**: Poor metabolizers maji dramaticky zvysene riziko toxicity - plasmaticke hladiny DXM mohou byt 10-20x vyssi!

---

## Plateauvý system

### Unikatni davkove-zavisla fenomenologie

DXM je znamy svym "plateau" systemem - ctyrmi kvalitativne odlisnymi urovnemi intoxikace:

| Plateau | Davka (mg/kg) | Davka (70kg) | Fenomenologie |
|---------|---------------|--------------|---------------|
| **1. plateau** | 1,5-2,5 | 100-175 mg | Stimulace, euforie, hudebni enhancement |
| **2. plateau** | 2,5-7,5 | 175-525 mg | Intoxikace, zmenena percepce, "robo-walk" |
| **3. plateau** | 7,5-15 | 525-1050 mg | Silna disociace, halucinace, zmatenost |
| **4. plateau** | >15 | >1050 mg | Uplna disociace, "hole", anesteticky stav |

### 1. Plateau - Stimulacni

| Aspekt | Popis |
|--------|-------|
| **Davka** | 100-200 mg |
| **Nastup** | 30-60 minut |
| **Trvani** | 4-6 hodin |
| **Charakter** | Podobne alkoholu, lehka stimulace |
| **Hudba** | Vyrazne zesílena |
| **Socialni** | Zvysena komunikativnost |
| **Rizika** | Nizka (pri cistych pripravcich) |

### 2. Plateau - Intoxikacni

| Aspekt | Popis |
|--------|-------|
| **Davka** | 200-500 mg |
| **Nastup** | 1-2 hodiny |
| **Trvani** | 6-8 hodin |
| **Charakter** | Silna intoxikace, euforicky |
| **Motorika** | "Robo-walk" - roboticka chuze |
| **Percepce** | Zmenene vnimani prostoru |
| **Closed-eye visuals** | Abstraktni vzory |
| **Rizika** | Stredni (nausea, ataxie) |

### 3. Plateau - Disociativni

| Aspekt | Popis |
|--------|-------|
| **Davka** | 500-1000 mg |
| **Nastup** | 1-3 hodiny |
| **Trvani** | 8-12 hodin |
| **Charakter** | Silna disociace, halucinace |
| **Telesnost** | Vyrazna anestetická |
| **Halucinace** | Open a closed-eye |
| **Mysleni** | Fragmentovane, konfuzni |
| **Rizika** | Vysoka (serotonin syndrom, tachykardie) |

### 4. Plateau - Anesteticky

| Aspekt | Popis |
|--------|-------|
| **Davka** | >1000 mg |
| **Charakter** | Uplna disociace, "DXM hole" |
| **Vedomi** | Minimalni az zadne |
| **Pamět** | Vyrazna amnézie |
| **Rizika** | Velmi vysoka (predavkovani, smrt) |

**VAROVANI**: 4. plateau je extrémne nebezpecne a muze vest k smrti!

---

## Bezpecnost

### Nezadouci ucinky

| Frekvence | Ucinky |
|-----------|--------|
| **Caste** | Nausea, zavrate, sedace, ataxie |
| **Stredni** | Tachykardie, hypertenze, hyperthermie |
| **Vzacne** | Psychoza, serotoninovy syndrom, rabdomyolyza |
| **Zavazne** | Respiracni deprese, koma, smrt |

### "Robo-itch" fenomen

Histaminergni reakce typicka pro DXM:
- Svědění, zvlášť obličej a trup
- Flush (zčervenání)
- Mechanismus: Nedostatečně objasněn (pravděpodobně sigma-1 mediovaný)
- Management: Antihistaminika (diphenhydramin - ale POZOR na interakce!)

### Serotonin syndrom - KRITICKE RIZIKO

DXM je **potentni SERT inhibitor** a kombinace s jinymi serotonergnimi latkami muze byt smrtelna:

| Nebezpecna kombinace | Riziko |
|----------------------|--------|
| **DXM + SSRI** | Vysoke |
| **DXM + SNRI** | Vysoke |
| **DXM + MAOI** | SMRTELNE |
| **DXM + Tramadol** | Vysoke |
| **DXM + MDMA** | Velmi vysoke |
| **DXM + Lithium** | Vysoke |

### Priznaky serotoninoveho syndromu

```
TRIADA:
1. Autonomni dysregulace
   - Tachykardie, hypertenze
   - Hyperthermie (>38C)
   - Poceni, prujem

2. Neuromuskularni abnormality
   - Hyperreflexie
   - Klonus
   - Tremor, rigidita

3. Zmeneny mentalní stav
   - Agitace
   - Zmatenost
   - Halucinace
```

### Olsen extraction

Nebezpecna praktiká ekstrahovani DXM z pripravku obsahujicich dalsi latky:

| Dalsi latka | Toxicita |
|-------------|----------|
| **Guaifenesin** | Nausea, zvraceni (vysoke davky) |
| **Acetaminofen (paracetamol)** | HEPATOTOXICKY - smrtelny! |
| **Chlorfeniramin** | Anticholinergni toxicita |
| **Fenylefrin** | Kardiovaskularni |

**ABSOLUTNI PRAVIDLO**: Pouzivat pouze pripravky s DXM jako jedinou aktivni latkou!

---

## Interakce

### Farmakokinetické (CYP2D6)

| Latka | Efekt | Dusledek |
|-------|-------|----------|
| **Quinidin** | CYP2D6 inhibitor | Zvyseny DXM, snizeny DXO |
| **Fluoxetin** | CYP2D6 inhibitor | Zvyseny DXM |
| **Paroxetin** | CYP2D6 inhibitor | Zvyseny DXM |
| **Bupropion** | CYP2D6 inhibitor | Zvyseny DXM (terapeuticke vyuziti!) |

### Farmakodynamicke

| Latka | Mechanismus | Riziko |
|-------|-------------|--------|
| **SSRI** | Aditivni serotonin | Serotonin syndrom |
| **MAOI** | Synergicke | FATALNI |
| **Ketamin** | Aditivni NMDA | Prilis silna disociace |
| **Alkohol** | CNS deprese | Respiracni deprese |
| **Benzodiazepiny** | CNS deprese | Respiracni deprese |

---

## Pravni status

### Mezinarodni

| Jurisdikce | Status |
|------------|--------|
| **USA** | OTC (s restrikci pro nezletile v nekterých státech) |
| **EU** | Variabilni - OTC az Rx |
| **Ceska republika** | Volne prodejne (Robitussin aj.) |
| **Australie** | OTC (nekteré formy Rx) |
| **UK** | OTC |

### Ceska republika

| Aspekt | Status |
|--------|--------|
| **Pravni status** | Nekontrolvana latka |
| **Dostupnost** | Volne prodejne v lekarnach |
| **Vekove omezeni** | Zadne oficiani (doporucene 18+) |
| **Pripravky** | Robitussin, Stopex, aj. |

---

## Terapeuticke pouziti

### Schvalene indikace

| Indikace | Davka | Forma |
|----------|-------|-------|
| **Neproduktivni kasel** | 10-30 mg q4-8h | OTC |
| **Pseudobulbarni afekt (PBA)** | DXM 20mg + Quinidin 10mg | Nuedexta |
| **Velka depresivni porucha** | DXM 45mg + Bupropion 105mg | Auvelity (2022) |

### Nuedexta - DXM v neurologii

**Pseudobulbarni afekt (PBA)**: Neurologicky stav s nekontrolovanym smichem/placem

| Mechanismus | DXM + Quinidin |
|-------------|----------------|
| **DXM** | Sigma-1 agonismus, NMDA modulace |
| **Quinidin** | CYP2D6 inhibice (zvysi DXM hladiny) |
| **Efektivita** | 49% redukce PBA epizod vs placebo |

### Auvelity - DXM v psychiatrii

**Schvaleno FDA 2022** pro MDD (velka depresivni porucha):

| Aspekt | Hodnota |
|--------|---------|
| **Slozeni** | DXM 45mg + Bupropion 105mg |
| **Mechanismus** | NMDA antagonismus + SERT inhibice + NE/DA modulace |
| **Nastup ucinku** | Rychlejsi nez tradicni AD (1-2 tydny) |
| **Efektivita** | MADRS -16 bodu vs -12 placebo |

---

## Vyzkum a budouci smery

### Aktivni oblasti

| Oblast | Status | Poznamka |
|--------|--------|----------|
| **Deprese** | FDA schvaleno (Auvelity) | Rychly nastup ucinku |
| **Agitace u Alzheimera** | Phase III | AVP-786 |
| **Neuropaticka bolest** | Preklinicke | Sigma-1 mediované |
| **Parkinsonova dyskineze** | Phase II | NMDA modulace |

### Mechanisticke studie

- Sigma-1 receptor v depresi
- NMDA-nezavisle ucinky DXM
- Neuroplasticita a BDNF
- Optimalni DXM:DXO pomer pro ruzne indikace

---

## Reference

### Farmakologie

1. Nguyen, L. et al. (2016). *Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders*. Pharmacology & Therapeutics.

2. Taylor, C.P. et al. (2016). *Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta)*. Pharmacology & Therapeutics.

3. Stahl, S.M. (2013). *Mechanism of action of dextromethorphan/quinidine*. CNS Spectrums.

### Klinicke studie

4. Iosifescu, D.V. et al. (2022). *Efficacy and Safety of AXS-05 in Major Depressive Disorder: A Phase 3 Study*. American Journal of Psychiatry.

5. Pioro, E.P. et al. (2010). *Dextromethorphan/quinidine for pseudobulbar affect*. Annals of Neurology.

### Toxikologie

6. Boyer, E.W. (2004). *Dextromethorphan abuse*. Pediatric Emergency Care.

7. Romanelli, F. & Smith, K.M. (2009). *Dextromethorphan abuse: Clinical effects and management*. Journal of the American Pharmacists Association.

---

## Krizove odkazy

### Souvisejici latky
- [Ketamin](@/alkaloids/ketamin.md) - Jiny NMDA antagonista
- [PCP](@/substances/pcp.md) - Strukturne a farmakologicky pribuzny
- [MXE](@/substances/mxe.md) - Designer disociativ

### Receptory
- [NMDA receptor](@/receptors/nmda.md) - Primarni disociativni cil
- [Sigma-1 receptor](@/receptors/sigma-1.md) - Neuroprotektivni cil
- [AMPA receptor](@/receptors/ampa.md) - Neprime ucinky

### Souvisejici temata
- [Serotonin](@/glossary/serotonin.md) - Serotoninergni aktivita DXM
- [Deprese](@/conditions/depression.md) - Terapeuticka indikace
- [Disociativa](@/classes/dissociatives.md) - Farmakologicka trida

---

Zpet na [Substance](@/substances/_index.md) | [Ketamin](@/alkaloids/ketamin.md) | [NMDA receptor](@/receptors/nmda.md)
